Company Profile

Neurorecovery, Inc. (NRI) is a late-stage biopharmaceutical company focused on peripheral neuropathies. The firm is dedicated to the development and commercialization of therapies that improve the functionality of the peripheral nervous system. Neurorecovery's lead product candidate is Ampydin® (IR) (4-Aminopyridine or 4-AP Immediate Release) which has shown promising results in Phase IIa and Phase IIb clinical trials. Phase IIa clinical trial was partially funded by a grant form the National Institute of Disability and Rehabilitation and Recovery (NIDRR). Phase IIb clinical trial was funded entirely by a grant from the Office of Orphan Products Development of the United States Food and Drug Administration. In December 2005, a meeting was held with the Neuro-Pharm division of the FDA. The objective of the meeting was to obtain regulatory approval to initiate Phase IIb – Part II clinical study. The outcome of that meeting was that the Neuro-Pharm division of the FDA granted Neurorecovery, Inc. a regulatory pathway to move into a Phase III clinical trial. On December 14, 2005, the firmalso received orphan drug designation of Ampydin® (IR) for the treatment of chronic functional motor and sensory deficits resulting from Guillain-Barre Syndrome (GBS). Orphan drug designation generally applies to a drug being developed for a rare disease or condition with marketing exclusivity for seven years in the U.S., if it is the first drug of its type approved for such indicati